Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRMT1 | Q99873 | 3/20 | 0.58 |
| ▸ | PRMT3 | O60678 | 1/20 | 0.54 |
| ▸ | EP300 | Q09472 | 1/20 | 0.54 |
| ▸ | PRMT6 | Q96LA8 | 1/20 | 0.54 |
| ▸ | CD40 | P25942 | 1/20 | 0.53 |
| ▸ | CD40LG | P29965 | 1/20 | 0.53 |
| ▸ | ENPP2 | Q13822 | 9/20 | 0.52 |
| ▸ | SIRT1 | Q96EB6 | 1/20 | 0.49 |
| ▸ | NT5E | P21589 | 1/20 | 0.42 |
| ▸ | CASP6 | P55212 | 1/20 | 0.41 |
| ▸ | CTDSP1 | Q9GZU7 | 1/20 | 0.41 |
| ▸ | GRIK1 | P39086 | 1/20 | 0.41 |
| ▸ | GRIK2 | Q13002 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6079026 | 0.99 | PRMT1 (0.60) | PRMT1PRMT3EP300PRMT6CD40 | |
| SCHEMBL6079021 | 0.86 | PRMT1 (0.60) | PRMT1PRMT3EP300PRMT6CD40 | |
| SCHEMBL10898946 | 0.77 | PRMT1 (0.73) | PRMT1PRMT3EP300PRMT6CD40 | |
| SCHEMBL11350653 | 0.75 | TIMP3 (0.55) | PRMT1PRMT3EP300PRMT6CD40 | |
| SCHEMBL29538633 | 0.74 | ENPP2 (0.86) | PRMT1PRMT3EP300PRMT6CD40 | |
| SCHEMBL2679101 | 0.74 | PRMT1 (1.00) | PRMT1CD40CD40LGENPP2SIRT1 | |
| SCHEMBL29349608 | 0.74 | PRMT1 (1.00) | PRMT1CD40CD40LGENPP2SIRT1 | |
| SCHEMBL6079067 | 0.74 | PRMT1 (1.00) | PRMT1CD40CD40LGENPP2SIRT1 | |
| SCHEMBL17277636 | 0.72 | CD40 (0.74) | PRMT1PRMT3EP300PRMT6CD40 | |
| SCHEMBL11340825 | 0.72 | TIMP3 (0.55) | PRMT1PRMT3EP300PRMT6ENPP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7071231-B2 | Naphthalene ureas as glucose uptake enhancers | TELIK, INC. (US) | 2006-07-04 | — | — | US | disclosed |
| EP-1181271-B1 | NAPHTHALENE UREAS AS GLUCOSE UPTAKE ENHANCERS | TELIK INC (US) | 2005-01-19 | — | — | EP | disclosed |
| US-20030135063-A1 | Novel naphthalene ureas as glucose uptake enhancers | SPEVAK WAYNE R (US) | 2003-07-17 | — | — | US | disclosed |
| US-6458998-B1 | NAPHTHALENEUREAS AS ANTIDIABETIC AGENTS | TELIK, INC. | 2002-10-01 | — | — | US | disclosed |
| EP-1181271-A2 | NAPHTHALENE UREAS AS GLUCOSE UPTAKE ENHANCERS | Telik, Inc. (US) | 2002-02-27 | — | — | EP | disclosed |
| WO-2000071506-A9 | NAPHTHALENE UREAS AS GLUCOSE UPTAKE ENHANCERS | TELIK INC (US) | 2001-09-20 | — | — | WO | disclosed |
| WO-2000071506-A2 | NAPHTHALENE UREAS AS GLUCOSE UPTAKE ENHANCERS | TELIK, INC. (US) | 2000-11-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030135063-A1 | Novel naphthalene ureas as glucose uptake enhancers | GPR119, SLC2A8, SLC2A1 | PRMT1 2899/4885PRMT3 3819/4885EP300 3413/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.